Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Short term Debt: 2019-2024

Historic Short term Debt for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $8.4 million.

  • Beam Therapeutics' Short term Debt fell 22.62% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 22.62%. This contributed to the annual value of $8.4 million for FY2024, which is 22.22% down from last year.
  • According to the latest figures from FY2024, Beam Therapeutics' Short term Debt is $8.4 million, which was down 22.22% from $10.8 million recorded in FY2023.
  • Beam Therapeutics' 5-year Short term Debt high stood at $71.2 million for FY2020, and its period low was $8.4 million during FY2024.
  • Its 3-year average for Short term Debt is $12.5 million, with a median of $10.8 million in 2023.
  • Its Short term Debt has fluctuated over the past 5 years, first spiked by 812.82% in 2020, then plummeted by 56.64% in 2022.
  • Yearly analysis of 5 years shows Beam Therapeutics' Short term Debt stood at $71.2 million in 2020, then slumped by 40.73% to $42.2 million in 2021, then slumped by 56.64% to $18.3 million in 2022, then slumped by 40.98% to $10.8 million in 2023, then declined by 22.22% to $8.4 million in 2024.